Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Although approved programmed cell death protein (PD)-1 inhibitors show durable responses, clinical benefits to these agents are only seen in one-third of patients in most cancer types. Therefore, strategies for improving the response to PD-1 inhibitor for treating various cancers including non-small...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jae-Won, Hong, Min Hee, Ha, Sang-Jun, Kim, Young-Joon, Cho, Byoung Chul, Lee, Insuk, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080767/
https://www.ncbi.nlm.nih.gov/pubmed/32879421
http://dx.doi.org/10.1038/s12276-020-00493-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080767/
https://www.ncbi.nlm.nih.gov/pubmed/32879421
http://dx.doi.org/10.1038/s12276-020-00493-8

Ejemplares similares